Zimmer Biomet (NYSE:ZBH) Earns Peer Perform Rating from Analysts at Wolfe Research

Wolfe Research started coverage on shares of Zimmer Biomet (NYSE:ZBH) in a research note published on Tuesday, MarketBeat.com reports. The firm issued a peer perform rating on the medical equipment provider’s stock.

A number of other research analysts have also commented on the stock. Needham & Company LLC reiterated a hold rating on shares of Zimmer Biomet in a research note on Thursday, August 8th. Morgan Stanley lowered their target price on Zimmer Biomet from $130.00 to $120.00 and set an equal weight rating on the stock in a research note on Monday, July 15th. Evercore ISI reaffirmed an in-line rating and issued a $113.00 price objective on shares of Zimmer Biomet in a report on Thursday, September 5th. The Goldman Sachs Group began coverage on Zimmer Biomet in a report on Thursday, May 30th. They set a neutral rating and a $129.00 target price for the company. Finally, UBS Group decreased their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a sell rating on the stock in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of Hold and an average target price of $125.72.

Zimmer Biomet Trading Down 0.0 %

Zimmer Biomet stock opened at $105.14 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. The stock has a 50-day simple moving average of $109.93 and a 200 day simple moving average of $116.30. The stock has a market capitalization of $21.63 billion, a P/E ratio of 22.76, a PEG ratio of 1.92 and a beta of 1.02. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same period in the previous year, the firm earned $1.82 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. Analysts expect that Zimmer Biomet will post 8.02 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.91%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc grew its holdings in shares of Zimmer Biomet by 10.1% during the fourth quarter. TD Asset Management Inc now owns 169,595 shares of the medical equipment provider’s stock worth $20,640,000 after purchasing an additional 15,552 shares during the last quarter. Bank of Nova Scotia raised its stake in shares of Zimmer Biomet by 499.0% during the fourth quarter. Bank of Nova Scotia now owns 134,729 shares of the medical equipment provider’s stock valued at $16,397,000 after acquiring an additional 112,237 shares during the last quarter. Speece Thorson Capital Group Inc. lifted its holdings in shares of Zimmer Biomet by 13.8% during the fourth quarter. Speece Thorson Capital Group Inc. now owns 158,202 shares of the medical equipment provider’s stock worth $19,253,000 after purchasing an additional 19,144 shares during the period. APG Asset Management US Inc. bought a new stake in shares of Zimmer Biomet in the fourth quarter worth $14,530,000. Finally, M&G Plc acquired a new stake in Zimmer Biomet in the first quarter valued at $7,397,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.